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 Abstract 
Rare genetic iron overload diseases are an evolving field due to major advances in genetics and molecular 
biology. Genetic iron overload has long been confined to the classical type 1 hemochromatosis related to the 
HFE C282Y mutation. Breakthroughs in the understanding of iron metabolism biology and molecular 
mechanisms led to the discovery of new genes and subsequently new types of hemochromatosis. To date four 
types of hemochromatosis have been identified: HFE-related or type1 hemochromatosis, the most frequent 
form in Caucasians, and four rare types, named type 2 (A and B) hemochromatosis (juvenile hemochromatosis 
due to hemojuvelin and hepcidin mutation), type 3 hemochromatosis (related to transferrin receptor 2 
mutation), and type 4 (A and B) hemochromatosis (ferroportin disease). The diagnosis relies on the 
comprehension of the involved physiological defect ,that can now be explored by biological and imaging tools, 
which allow non invasive assessment of iron metabolism. A multidisciplinary approach is essential to support 
the physicians in the diagnosis and management of those rare diseases.  
 
 Introduction 
Since the description of Hemochromatosis by Trousseau in 1865, and the demonstration of its genetic nature 
1
, 
many studies have shed light on its putative pathophysiological mechanism. The first major breakthrough was 
the discovery of the HFE gene 
2
. This made it possible to diagnose the most common form of hereditary 
hemochromatosis (HFE or Type 1 hemochromatosis) due to the p.Cys282Tyr mutation (C282Y) in the HFE gene. 
Further discoveries unraveled iron metabolism regulation and its molecular mechanism, leading to the 
description of new and rarer form of hemochromatosis which are referred as non HFE hemochromatosis. 
Hepcidin, which is coded by the HAMP gene 
3
, plays a central role
4,5
. Mainly secreted by the liver
6,7
, this small 
peptide was shown to interact with ferroportin
8
 (coded by the SLC40A1 gene), the only known cellular iron 
exporter, this interaction inducing ferroportin internalization and degradation. Thus, through its regulation of 
ferroportin, hepcidin can reduce iron export from macrophages and enterocytes into the bloodstream. The 
Transferrin Receptor 2
9,10
 (TFR2, coded by the TFR2 gene) and Hemojuvelin 
11-13
(coded by the HJV gene) are 
critical cofactors in hepcidin secretion regulation. Each of these genes can have mutation leading to different 
peculiar forms of Hemochromatosis, whose phenotypical expression can share common signs or have specific 
features. These discoveries, and the broader availability of genetic testing, enabled a better discrimination of 
HFE and non-HFE related Hemochromatosis from various secondary causes of iron overload. However, if 
physiology needs to be known for enlightening the expression of these conditions, it makes the diagnosis 
workup more complex since the phenotype can be mixed and the appropriate tests to perform difficult to 
choose. This emphasizes the relevant role of referral centers who can provide guidelines, genetic advice, and 
in-house genotyping testing to support physicians for proper evaluation of their patients with suspected rare 
genetic iron overload syndromes. 
 
 
 
 
 PHYSIOLOGY AND PATHOLOGY 
 
IRON METABOLISM 
 
IRON UPTAKE AND EXPORT 
 
Iron uptake occurs in the proximal part of the duodenum where two forms of iron are available: heme iron, 
mainly found in meat from the degradation of myoglobin and hemoglobin, and non heme iron found in 
vegetable and grains. Heme iron is carried out by endocytosis through the apical membrane of enterocytes, 
possibly by the Heme Carrier Protein 1
14
; the subsequent catabolism pathways are not yet definitely 
demonstrated. Non heme iron is transported into the cytoplasm of enterocytes by Divalent Metal Transporter 
1(DMT1)
15
. Ferroportin (SLCA40A1)
16-18
 is the only known cell iron exporter, located at the basal membrane of 
enterocytes and  at the membrane of macrophages, where it allows iron egress from the cytoplasm to the 
bloodstream with subsequent oxidation by hephaestin 
19
 and  binding to transferrin  (Figure 1). 
HEPCIDIN 
 
Hepcidin (HAMP) is a small peptide, first identified as an antimicrobial peptide
4-6
. Mainly synthesized in the 
liver by hepatocytes, it is also produced at a lower level by adipocytes
20
 and macrophages
21
. Highly expressed 
in iron overload and inflammation 
4,22
, hepcidin was later shown to be the key hormone of iron metabolism 
regulation
7,23,24
. Hepcidin interacts with ferroportin: circulating hepcidin binds to membrane ferroportin and 
causes subsequent ferroportin internalization and degradation 
8
 (Figure 1). As a consequence, cellular iron 
egress is impaired. Hepcidin causes hypoferremia by decreasing cellular release into the plasma
25
, therefore 
regulating body iron availability through influencing iron release by both enterocytes and macrophages. 
HEPCIDIN REGULATION 
 
The regulation of hepcidin expression has been mainly studied at a transcriptional level 
26
. In inflammation, 
hepcidin induction results from the signaling of interleukin-6 through its receptor and STAT3 
27-30
 (signal 
transducer and activator of STAT3). Basal expression is regulated through a bone morphogenetic protein (BMP) 
/SMAD pathway 
12,31-33
. BMP6 
34,35
 is thought to play a major role in association with its coreceptor 
hemojuvelin
11-13
 (HJV), and is also involved in the response of hepcidin expression to iron stores 
36
. Although 
molecular mechanisms remain not fully elucidated, it is currently accepted that HFE, TFR1, TFR2 and HJV form a 
complex at the hepatocyte membrane 
37-39
, which is thought to play a major role in the sensing of iron stores 
according to serum transferrin saturation, with subsequent regulation of hepcidin expression
9,40,41
 (Figure 1). 
TFR2 has been reported to activate signal transduction involving MAP kinase pathway 
42
. A post-traductional 
level of hepcidin activity control, which implicates the furin dependent cleavage process, has been recently 
highlighted 
43,44
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IRON OVERLOAD 
Iron overload arising from mutations in genes involved in iron metabolism are induced by two types of 
mechanisms 
HEPCIDIN DEFICIENCY 
 
Hepcidin deficiency is the key mechanism explaining iron overload in type HFE, HJV, HAMP and TFR2 related 
hemochromatosis. The corresponding mutations lead, through disturbances of signal induction cascades, to 
decreased hepatic synthesis of hepcidin. In HFE hemochromatosis it was demonstrated in mice and confirmed 
in humans that correction of liver hepcidin secretion normalized iron metabolism 
45,46
. Hepcidin deficiency 
leads to a sustained and unregulated activity of ferroportin with a double patho-physiological consequence 
5,47
. 
On one hand, it leads to increased duodenal absorption of iron, and on the other hand, it enhances the release 
by macrophages into the blood of splenic iron originating from erythrophagocytosis. The overall result is 
increased plasma iron concentration associated to increased transferrin saturation. Beyond a certain level of 
transferrin saturation, peculiar biochemical iron species appear, named non-transferrin bound iron (NTBI) 
48,49
. 
NTBI has the property to be very rapidly taken up by the liver 
50
, pancreas and heart, and therefore produces 
parenchymal iron excess (namely hepatocytes for the liver). Moreover, an NTBI component, called labile 
plasma iron (LPI) 
51,52
, which appears whenever plasma transferrin saturation is over 75%, corresponds to a 
potentially damaging iron species due to its high propensity for generating reactive oxygen species. 
 
 
 
 
 
IRON TRANSPORT ANOMALIES 
 The iron exporter Ferroportin can be involved in two types of diseases. In type A, mutations lead to a loss of 
activity of the protein
53
, and iron overload is related to decreased iron release from the macrophages as a 
consequence of functional deficiency. Conversely, in type B, the mutated ferroportin becomes resistant to 
hepcidin action 
54
, thus despite an increased serum hepcidin level, the resulting “functional hepcidin 
deficiency” produces, through decreased ferroportin degradation, an increased ferroportin activity as in HFE 
hemochromatosis. 
Mutations of the ceruloplasmin gene can hamper its ferroxydase activity (which transforms ferrous iron into 
ferric iron) which is mandatory for iron uptake by circulating transferrin after iron has been exported by 
ferroportin. As a consequence, excessive ferroportin degradation may occur, leading to decreased cellular 
export of iron 
55
. 
 
As one can see, in types HFE, HJV, TFR2, HAMP, and type B ferroportin hemochromatosis, cellular iron excess is 
due to an hepcidin deficiency with increased entry of excessive plasma iron into cells (predominantly 
parenchymal cells) whereas, in types A ferroportin disease and in hereditary aceruloplasminemia, cellular iron 
overload is related to decreased iron egress from cells with low circulating iron. These two different 
mechanisms have important implications both for the phenotypic expression of the diseases and for their 
therapeutic approaches.  
 
 
 
 
 
 
 
 
ETIOLOGY 
Actors of iron metabolism can suffer genetic alterations leading to perturbations of its physiological 
equilibrium. According to theinvolved genes and subsequent affected mechanisms, the phenotypes differ, thus 
dividing hemochromatosis in different subtypes. 
HFE-RELATED (TYPE 1) HEMOCHROMATOSIS 
 
HFE related hemochromatosis 
56
 is the classical, and first described form, of genetic iron overload. The HFE 
gene located on chromosome 6 codes for the membrane protein HFE, a MCH-Like protein whose definite role 
at the membrane remains unclear. Associated with β2-globulin, TFR1 and potentially TFR2 and HJV, it plays a 
critical role in iron load sensing to regulate hepcidin secretion
9,37-40
. However, the definite subsequent signaling 
cascade, although interacting with the BMP/SMAD pathway, remains to be determined. Alterations in the 
protein can eventually lead to a decreased and unregulated hepcidin secretion, promoting iron absorption and 
iron overload 
57-61
. The paramount role of liver in this alteration of iron metabolism has been proven by its 
evolution after liver transplantation in humans
46
. 
The most frequent and classical mutation of this gene is the p.Cys282Tyr (C282Y) mutation, which can lead to 
iron overload when present in the homozygous state 
62
. The mutation prevalence is high in Caucasian 
populations 
63,64
 (10% of the subjects are heterozygous, 3 to 5 subjects per thousand are homozygous), but 
almost absent in the non Caucasian populations 
65
. Other genotypes than C282Y homozygosity cannot explain 
overt hemochromatosis : C282Y heterozygosity, H63D heterozygosity or homozygosity and compound 
heterozygosity C282Y/H63D do not result in clinically significant iron overload in the absence of cofactors 
accounting for disturbed iron metabolism (alcoholism or metabolic syndrome) 
66,67
. However some patients 
with compound heterozygosity C282Y/H63D may have, even without known cofactors, increased transferrin 
saturation and serum ferritin suggesting mild to moderate iron overload. Although they won’t develop overt 
iron overload, and because many patients with C282Y homozygosity will also have only mild to moderate iron 
overload, the clinical relevance of compound heterozygosity is still debated. Moreover there is currently no 
data to define, biologically or clinically, what is a significant iron overload advocating for further diagnosis 
workup. Thus the role of compound heterozygosity in the diagnosis remains elusive in clinical guidelines
68,69
. 
Other rare (private) mutations of the HFE gene have been described associated to those frequent genotypes, 
thus explaining cases of iron overload 
70
.  
The phenotypic expression of C282Y homozygosity is quite variable, and the full-blown form of the disease 
(especially with cirrhosis) is rare 
71-74
. Given that C282Y homozygosity is necessary but not sufficient for iron 
overload development, the role of modifying factors, impacting iron metabolism or hepcidin secretion, has 
been advocated. These factors can be acquired (diet 
75,76
, alcohol 
77,78
, hepatic dysfunction 
59
, metabolic 
syndrome 
20,79,80
), or genetic (gender-related
63,64,71,81
 or iron genes-related factors: well documented in mice 
82-
84
, the modifying role of associated genes of iron metabolism appears more mitigated in humans 
85-89
). 
JUVENILE (TYPE 2) HEMOCHROMATOSIS 
Described before the availability of genetic testing 
90
 this rare disease encompasses two entities characterized 
by the usual young age at diagnosis. Type 2A hemochromatosis is due to mutation of the hemojuvelin (HJV) 
gene 
91
 on chromosome 1 and type 2B is due to mutations of the hepcidin (HAMP) gene 
92
 itself, located on 
chromosome 19. Both are autosomal recessive diseases. It is a particularly severe form of hemochromatosis, 
usually affecting young patients (<30 years old), often associated with cardiac involvement and central 
endocrine impact (hypogonadotropic hypogonadism). Iron overload is massive and liver fibrosis is frequent 
although cardiac and endocrine manifestations are at the forefront. The major and early impact of HJV 
mutations on metabolism emphasizes its critical role in hepcidin secretion regulation. Hemojuvelin is expressed 
in muscle and liver, but iron metabolism is under the sole regulation of hepatocyte expressed hemojuvelin 
93
. 
At the membrane of the hepatocyte, hemojuvelin act as a BMPs coreceptor modulating the BMP/SMAD 
pathway eventually enhancing hepcidin expression. Mutations of HAMP have obvious direct impact on 
hepcidin synthesis. Moreover, when associated with other form of hemochromatosis, mutations in the 
promoting region of HAMP have been described as a worsening factor of iron overload 
94
. 
 
 
 
 
  
 
 
TFR2 RELATED (TYPE 3) HEMOCHROMATOSIS 
 
Type 3 related hemochromatosis is an autosomal recessive disease that can be considered as an 
“intermediate” disease between juvenile and HFE hemochromatosis. Caused by mutations of the transferrin 
receptor 2 gene (TFR2) located on chromosome 7, its clinical picture mimics HFE hemochromatosis although 
patients are usually younger and iron overload more severe
95-101
. Age of onset is usually described to be young 
adulthood (>30 years old) although several report of children with type 3 hemochromatosis do suggest that 
peculiar genotypes or cofactors could lead to more severe and earlier diseases 
100,102
. Cardiac and endocrine 
dysfunctions are less frequent than in juvenile hemochromatosis. Arthropathy is not rare. TFR2 is undoubtedly 
involved in hepcidin expression regulation, but its molecular mechanism remains unclear. TFR2 is 
complementary to HFE for hepcidin regulation according to iron load sensing 
9,40
. Moreover, TFR2 is supposed 
to interact with HFE at the hepatocyte membrane and may modulate the BMP/SMAP pathway through a cross 
talk involving the MAP/Erk signaling pathway 
42
.  
FERROPORTIN DISEASE – TYPE 4 HEMOCHROMATOSIS 
 
This disease is due to mutations of the ferroportin (SLC40A1) gene located on chromosome 2 
103,104
. Unlike 
other types of hemochromatosis, inheritance is autosomal dominant. Although rare, it is more frequent than 
types 2 and 3 hemochromatosis and has been reported worldwide 
105-107
. According to phenotypic expression it 
can be subdivided in two subtypes: i) Type A, the classical form, is characterized by normal or low transferrin 
saturation and liver biopsy shows macrophagic iron deposition ; ii) Type B variant which is more rare, is similar 
to types 1 and 3 hemochromatosis with elevated transferrin saturation and parenchymal iron deposition. 
Overall, the clinical manifestations of ferroportin disease are limited 
108
, with only seldom cases of liver damage 
reported which were frequently associated with cofactors. Liver damage may be more frequent in type B than 
in type A 
109,110
. 
As afore-mentioned, Ferroportin is the only know iron exporter at the cell membrane. In type A ferroportin 
disease, mutations lead to loss of iron-export function and cause iron accumulation within macrophages 
accounting for the predominant spleen iron overload seen by magnetic resonance imaging. Theoretically 
trapped in the macrophages, iron biological availability is low explaining the normal or low transferrin 
saturation and the potentially lower tolerance to venesections than in HFE hemochromatosis. In type B 
ferroportin disease, mutations lead to resistance of ferroportin to hepcidin activity, resulting in an excessive 
cellular iron efflux. Thus, the phenotypic picture mimicks that of type 1 Hemochromatosis with increased 
serum iron and transferring saturation, and parenchymal iron deposition. 
OTHER RARE IRON OVERLOAD DISEASES 
 
Hereditary a(hypo)ceruloplasminemia is due to mutations of the ceruloplasmin gene 
111
, which either totally  
inhibit protein production 
112
 or its ferroxidase activity 
113
. Clinically, iron overload is associated with anemia 
and neurological symptoms. Other rare entities are presenting as anemia and iron overload syndromes: they 
are related to mutations of transferrin (atransferrinemia)
114
, DMT1 (Divalent Metal Transporter1)
115-118
, X linked 
sideroblastic anemia (ALAS2
119
, ABC7
120
) , or glutaredoxin 5 (GRLX5) genes 
121
.  
 
 DIAGNOSIS WORK UP 
 
The diagnosis work up of iron overload involves crucial steps to avoid misleading diagnosis due to confounding 
factors, and to optimize resource utilization. Many tools have been made available to help the physicians in this 
sequential strategy. Reference centers can ultimately be of primary importance to discuss difficult cases and 
assess the need for further specific explorations. 
 
CAUSES OF REFERRAL, CLINICAL PRESENTATION  
 
Clinical features associated with iron overload are diverse and can be more or less associated: asthenia, 
impotence due to endocrinopathy, arthropathy and osteopenia, skin darkening, hepatomegaly and  moderate 
transaminase increase, diabetes, cardiomyopathy (cardiac failure or rhythm disturbance). However, due to 
improved knowledge of the disease and more widespread screening, the currently major cause of referral is 
elevated serum ferritin level, detected in the context of suspected iron overload, or uncovered during routine 
biological check-up or work up for other suspected diseases.  
 
TO ASCERTAIN IRON OVERLOAD 
 
The first step is to confirm that elevated serum ferritin is related to iron overload by assessing potential 
confounding factors, thus avoiding unnecessary explorations. This step is crucial and can be difficult as many 
frequent conditions can alter serum ferritin levels. Moreover, some of these causes can be associated with iron 
overload further increasing serum ferritin concentration.  
 
 CONFOUNDING CAUSES OF HIGH SERUM FERRITIN 
 
ALCOHOL CONSUMPTION 
 
Alcohol can increase serum ferritin levels by different direct means: alcohol itself can induce ferritin synthesis 
122
, and inhibit hepcidin synthesis which can lead to mild iron overload 
78
. Moreover, alcohol can increase 
serum ferritin by indirect means: as hepatocytes are the main storage sites of ferritin, cell lysis related to 
alcoholic liver disease leads to release of ferritin in the bloodstream. Thus, serum ferritin should be interpreted 
with care in case of alcohol consumption and should be, if possible, controlled after a few months of 
abstinence. It should be kept in mind that marked fluctuations of serum ferritin levels are highly suggestive  of  
intermittent phases of excessive alcohol consumption. 
METABOLIC SYNDROME 
 
 The definition of the metabolic syndrome initially suffered of controversy, but is now admitted to be
123
 : 
- Increased waist circumference (94cm in man and 80 in women, with population specific definitions) 
- Increased triglycerides (or specific treatment): > 1.7 mmol/L 
- Reduced HDL cholesterol (or specific treatment): < 1 mmol/L in men and 1.3 mmol/L in women 
- Increased blood pressure (or specific treatment): Systolic ≥130 and/or diastolic ≥85 mm Hg 
- Increased fasting glucose (or specific treatment) : >5.5 mmol/L 
Metabolic syndrome is one of the most frequent causes of hyperferritinemia. Metabolic syndrome can be 
associated with hyperferritinemia (often comprised between 500 and 1200 µg/L) without or with mild iron 
overload 
124
 (insulin resistance associated iron overload or dysmetabolic hepatosiderosis) and is usually 
associated with increased serum hepcidin levels 
125
. However, iron burden remains of lower intensity as 
compared to the pronounced serum ferritin increase. Serum transferrin saturation is usually normal although it 
can sometimes be slightly increased. It leads frequently to an erroneous diagnosis of hemochromatosis. 
INFLAMMATION 
 
In the acute or chronic phase of inflammation, ferritin can be mobilized without iron excess, thus leading to 
high serum ferritin which can range from mild to very high levels. One should think of inflammation especially 
when serum iron is low. Therefore plasma C reactive protein (CRP) should always be part of the work up for 
hyperferritinemia. 
LIVER DAMAGE 
 
Acute or chronic liver injury resulting in hepatocyte damage can lead to increased serum ferritin regardless of 
the underlying cause. Actually, ferritin is mainly stored in hepatocytes and serum ferritin is a only minor part of 
total body ferritin stores and is used as a surrogate marker. Thus, similarly to aspartate amino transferase and 
alanine aminotransferase, intracellular ferritin can be released into the bloodstream secondary to hepatocyte 
injury. The determination of serum transaminase activities is therefore another important parameter to control 
for proper interpretation of hyperferritinemia. 
 
 
 
 
 
 
  
 
RARE CAUSES OF ELEVATED SERUM FERRITIN 
 
Some peculiar conditions can be associated with high serum ferritin without iron overload 
 
• Hereditary Hyperferritinemia-Cataract Syndrome 
 
Mutation in the Iron Responsive Element in the non-coding region of the messenger RNA of the L-Ferritin gene 
(FTL, coding for the light subunit of ferritin) causes hyperferritinemia (which can be very elevated, often above 
1000 µg/L) associated, in the classical form, with an history of familial cataracts, often expressed in young 
subjects and leading to early surgical treatment 
126-128
. Transmission is autosomal dominant. This condition is 
not associated with iron overload and thus there is no indication for venesection therapy. Although long term 
data are scarce, there is currently no data that advocate for a negative consequence of chronically elevated 
serum ferritin in this context. Beside this classical form, mutations in the coding region of the FTL gene have 
been recently described
127
. Those mutations, referred to as Hereditary L Ferritin syndrome in figure 2, lead to 
elevated serum ferritin without iron overload or cataract.  
 
• Gaucher’s disease 
 
Gaucher’s disease can be associated with high serum ferritin and normal transferrin saturation. It is an 
inherited metabolism anomaly (glucocerebrosidase deficiency) resulting in excessive storage of 
glucocerebroside in the liver, spleen, bone, and bone marrow. The clinical signs are anemia, thrombocytopenia, 
hepatosplenomegaly, and bone pain. Elevated serum ferritin is not at the forefront of the clinical picture and 
should not postpone referral to a referent center.   
 • Macrophage activation syndrome 
 
Hyperferritinemia, which is a diagnosis criteria, is massively elevated (>5000 µg/L) in the context of infectious 
(EBV), inflammatory (Still’s syndrome) or hematological diseases. It is associated with general symptoms (fever, 
splenomegaly, cytopenia, high serum triglyceride levels) that need urgent referral for treatment. 
TO QUANTIFY IRON OVERLOAD 
 
Once iron overload is suspected by elevated serum ferritin, and the potential confounding factors have been 
assessed, the next step is to assess body iron stores to quantify iron overload. Serum transferrin saturation 
should first be performed. If elevated HFE related hemochromatosis is the most likely diagnosis in the 
Caucasian population and should thus be confirmed by HFE C282Y testing before further exploration. Lack of 
C282Y homozygosity requires definite evaluation of iron overload. 
Using the paramagnetic property of iron, Magnetic resonance imaging (MRI) is a fast and efficient non invasive 
technique to assess liver iron concentration 
129,130
. It requires an 1,5 Tesla MRI device (which is the most 
frequent) and the algorithm for iron evaluation proposed by the Rennes University is freely accessible on the 
website www.radio.univ-rennes1.fr. 
A region of interest is drawn to compare the T2 signal between liver and paravertebral muscle, hyposignal 
(meaning dark liver as compared to paravertebral muscles), representing higher tissue iron concentrations. The 
very good correlation between hyposignal and hepatic iron overload allows to determine hepatic iron 
concentration with a satisfactory reliability. Moreover, it is highly relevant to evaluate hepatic versus an 
approximation of splenic iron load since a dominant splenic iron excess means preferential macrophagic iron 
deposition, therefore orientating the diagnosis towards transfusional iron excess or ferroportin disease 
131
. 
Alternative methods, using T2 relaxometry have been developed and are found to be more accurate to 
quantify liver iron content at all levels of iron overload
130,132
. However due to hardware requirement and lack of 
standardization they are not yet widely available.  
If MRI is not available or contra-indicated, liver biopsy, using Perls staining, remains a reference method for 
diagnosing iron excess 
133
. Biochemical determination of iron concentration remains the gold standard. 
Moreover, liver biopsy gives definite information regarding parenchymal or mesenchymal localization of iron 
overload which can be helpful in the diagnosis workup (review in Deugnier et al.
134
). However, due to its 
invasive nature, morbidity, cost and the increasing place of MRI, liver biopsy is rarely needed for diagnosing the 
type of iron overload. Indications today are mainly to evaluate iron overload consequences in terms of hepatic 
fibrosis and to search for possible co-factors such as steatohepatitis (alcoholic or not (NASH)). Regarding 
fibrosis evaluation, there is growing evidence that non invasive procedures such as serum markers and/or 
transient elastography, can give relevant information
135,136
.  
 
 
 
PRIMARY OR SECONDARY IRON OVERLOAD 
 
Once iron overload has been identified and quantified, its primary or secondary nature must be determined. 
Oral supplementation, although rarely, can lead to iron overload 
137
. It is thus necessary, through careful 
questioning, to ensure that the patient has not undergone prolonged iron supplementation. It is of major 
importance to assess this point in patient seeking sportive performance for professional 
138
 or non-professional 
reasons, as it has been considered that iron supplementation could increase hemoglobin status.  
The main cause of secondary iron overload is represented by hematological conditions. Chronic or rare 
anemias such as thalassemia major, sickle cell disease, myelodysplatic syndromes, and congenital anemias, can 
be associated with iron overload. 
Two, more or less associated, mechanisms can be involved:  
- Increased iron load through repeated transfusions represents, a major cause of iron overload (each 
transfused unit provides 200–250 mg of iron so that significant iron excess develops after 10–20 units). This 
mechanism leads to an increased recycling of red blood cells process with enhanced iron deposition within 
macrophages, mainly in the spleen but also in hepatic Kupffer cells. 
- Hepcidin deficiency. Ineffective erythropoiesis leads, through a yet not clearly defined pathway, to inhibition 
of hepcidin expression. The proposed role of Growth Differentiation Factor 15 
139
is now questioned  since a 
more direct link between erythropoiesis and hepcidin secretion has been recently reported. Indeed, a major 
breakthrough is represented by the discovery of the hormone named erythroferrone which corresponds very 
likely to the long-sought “erythropoietic factor” (Kautz et al, 2013, BioIron, London).   This could explain why 
iron overload can develop in chronic anemia, like thalassaemia, even in the absence of transfusions 
140
, and 
why hepcidin expression is relatively low in those diseases despite transfusional iron excess (which should lead 
to increased hepcidin expression).  
Past history of chemotherapy treatment should also be sought. Growth factor or sometimes multiple 
transfusions used in this context can also lead to iron overload. The long term outcome of “transitional” 
secondary iron overload is not known, but due to the absence of natural and effective iron elimination route, it 
is likely that iron overload can persist for years. 
TO IDENTIFY THE GENETIC ORIGIN OF IRON OVERLOAD 
 
Identification of the genetic cause of primary iron overload is driven by the combination of patient’s clinical and 
biological data that suggest the possible underlying physiological mechanism. 
A precise determination of the suspected disease is highly recommended as most of the genetic studies are not 
performed in routine and are both expensive and time consuming. Thus, a multidisciplinary approach is often 
required in complex cases and the help of referral centers should be sought. 
As an example, in France,  a national reference center, working in a nextwork with several regional competence 
centers, has been established (http://www.centre-reference-fer-rennes.org/) and proposes, on a weekly basis, 
multidisciplinary meetings where difficult cases are discussed in order to support physicians in their diagnosis 
work-up. 
 PATIENT AND FAMILY DATA 
Patient’s clinical and biological data have to be gathered through the initial phases of work-up. It should be 
emphasized that, due to important between and within-day variations of iron biological parameters (especially 
serum iron and transferrin saturation 
141,142
), repeated measurements should be performed especially to avoid 
false positive results. 
 
Family history is a major point to assess. Careful search for putative diagnosis of iron overload in relatives can 
suggest the presence of a dominant or recessive disease and strengthen the need for genetic exploration. 
 
DECISION TREE 
 
The decision tree is summarized in Figure 2.  
Serum transferrin saturation is the initial key point. 
 
• Increased transferrin saturation 
 
The most likely diagnosis in Caucasians is HFE related (or type 1) hemochromatosis as confirmed by C282Y 
homozygosity. If there is a family history of dominant transmission the type B ferroportin disease 
(hemochromatosis 4B) should be sought.  
If the C282Y HFE mutation is absent, the next relevant information is the age of presentation: in young patients 
(<30 years old) either type A (hemojuvelin mutations) or type B (hepcidin mutation) juvenile hemochromatosis 
(type 2 hemochromatosis) should be looked for. In older patients, transferrin receptor 2 mutation (or type 3 
hemochromatosis), type B ferroportin disease (hemochromatosis 4B) or private mutations of the HFE gene 
(which require complete sequencing of the gene instead of routine HFE C282Y test) can be evoked. However 
patient with very early presentation of type 3 hemochromatosis have been reported, and conversely patient 
with type 2 hemochromatosis and late presentation have also been reported. Thus if age is a clue for deciding 
which genetic test should be performed at first, if negative an unusual age of presentation must be considered. 
 
• Normal or low transferrin saturation  
 
In this case, the most likely diagnosis is the classical form of ferroportin disease (type A) which can be 
confirmed be sequencing. However, given its simplicity, plasma ceruloplasmin levels should also be determined 
despite the rarity of hereditary aceruloplasminemia. The latter diagnosis will of course be more likely in cases 
of anemia and/or neurological symptoms. Ceruloplasmin levels are typically not detectable but, in some cases, 
ceruloplasminemia is only significantly decreased. 
 
 
 
MANAGEMENT OF NON HFE HEMOCHROMATOSIS 
FAMILY SCREENING 
Family screening is very important in the management of patients with genetic iron overload. It can provide 
precious clues in the diagnosis work-up of the patient but  also help to determine if a genetic anomaly is a 
pathogenic mutation or a simple polymorphism by studying the genotype / phenotype correlations within the 
family. Mostly, family screening, following the diagnosis of  a specific mutation in a given patient, allows earlier 
diagnosis thus preventing the development of iron-related organ damage related . 
PHLEBOTOMY 
The mainstay of treatment in genetic iron overload is removal of iron burden. Phlebotomies (venesections) 
remain the most efficient and convenient way to remove iron by forcing the bone marrow to use stored iron 
for intense erythropoiesis. 
Treatment is performed in non-HFE hemochromatosis in a similar way to that of the type 1 form. The initial 
induction phase will remove the excessive iron and the maintenance phase will prevent its recurrence 
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. 
During induction phase, phlebotomy is performed on a weekly basis using a weight based volume of 7ml/Kg up 
to 550ml. Hemoglobin should be monitored on a monthly basis. In case of anemia treatment should be 
postponed until resolution ; if necessary volume and / or frequency of phlebotomy should be reduced. Serum 
ferritin is monitored to assess treatment efficiency. Monitoring frequency relies upon serum ferritin value: 
monthly as long as ferritin remains above the normal range, then fortnightly until the goal of 50µg/L is reached.  
Once iron depletion has been achieved, the aim of maintenance treatment is to prevent recurrence of iron 
overload. Venesection is thus performed every 2-4 months to maintain a serum ferritin value close to 50µg/L.   
Special attention should be given to iron overload related to iron transport anomalies, like ferroportin disease, 
as anemia could occur more frequently. Therefore, hemoglobin levels should be closely monitored and 
phlebotomies should be performed initially less frequently to test for hematological tolerance. 
OTHER THERAPEUTIC ASPECTS 
DIET 
 
Although very commonly questioned by patients, and probably partially involved in the variable expression of 
the disease, no studies showed beneficial effect of dietary modification or alimentary iron avoidance in patient 
undergoing phlebotomy treatment. Thus, it is advised to maintain a healthy diet without stringent restrictions 
regarding iron. However, iron supplemented food should be avoided and it is usually recommended to limit 
vitamin C intake due to its possible toxic effect. 
Special emphasis should be given to alcohol consumption. It has been clearly shown that, like in many liver 
diseases, excessive alcohol consumption increases liver damage 
77
. Moreover, a direct inhibition effect of 
alcohol on hepcidin secretion favors iron overload.  
ORAL CHELATION 
 
Deferasirox (Exjade®) is an oral iron chelator, which, taken once daily, is used in post-transfusional iron 
overload. An international study in HFE hemochromatosis showed satisfactory results regarding safety and 
efficiency 
144
. Although off label, this treatment could be helpful in case of contraindication (anemia) or poor 
tolerance to phlebotomy. Moreover, it could be useful, in addition to venesections, in patients with massive 
iron overload and organ damage requiring very rapid removal of iron burden. 
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 LEGENDS TO FIGURE 
Figure 1: Iron metabolism regulation. HCP : Heme carrier protein. DMT1 : Divalent Metal Transporter 1. HJV : 
Hemojuvelin. TFR1 : Transferrin Receptor 1. TFR2 : Transferrin Receptor 2. BMP Receptor : Bone Morphegenic 
Protein receptor. 
 
 
 
 
 
 
Figure 2: Decision tree for diagnosis of genetic iron overload. HC : Hemochromatosis 
 
